SP-8356，一种合成的抗炎的Verbenone衍生物，是一种有效的、口服活性的分化147(CD147)抑制剂。SP-835抑制CD147-环磷酰胺A(CypA)相互作用，降低MMP-9活性。SP-8356通过抑制NF-κB信号传导发挥抗乳腺癌作用。具有抗动脉粥样硬化作用。
货号:ajcx31488
CAS:1454885-45-0
分子式:C18H20O4
分子量：300.35
溶解度:DMSO: 100 mg/mL (332.94 mM)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

SP-8356, an anti-inflammatory synthetic Verbenone derivative, is a potent, orally active cluster of differentiation 147 (CD147) inhibitor. SP-8356 inhibits CD147-cyclophilin A (CypA) interaction and reduces MMP-9 activity. SP-8356 exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects[1][2][3].

SP-8356 (5-10 μM; 48 hours) inhibits growth of various types of breast cancer cell lines in a time- and dose-dependent manner[1].SP-8356 (10 μM; 48 hours) increases percentage of MDA-MB231 cells in S phase and decreases casapas-3 and cleaved PARP[1]. Cell Proliferation Assay[1] Cell Line: MDA-MB231, MDA-MB453, 4T1, and MCF-7 cells

SP-8356 (10 mg/kg; i.p.; every three days until the 42nd day) inhibits tumor growth in a xenograft mouse model[1].SP-8356 (50 mg/kg; p.o.; daily one day after carotid artery ligation for three weeks) prevents the formation of plaque and attenuates its vulnerability[2]. Animal Model: Five-week-old female NOD/SCID mice (MDA-MB231 xenografts)[1]

[1]. Mander S, et al. SP-8356, a (1S)-(-)-verbenone derivative, exerts in vitro and in vivo anti-breast cancer effects by inhibiting NF-κB signaling. Sci Rep. 2019 Apr 29;9(1):6595. [2]. Pahk K, et al. SP-8356, a Novel Inhibitor of CD147-Cyclophilin A Interactions, Reduces Plaque Progression and Stabilizes Vulnerable Plaques in apoE-Deficient Mice. Int J Mol Sci. 2019 Dec 21;21(1). pii: E95. [3]. Pahk K, et al. A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation. J Transl Med. 2019 Aug 20;17(1):274.